GlaxoSmithKline (GSK) has invested $36 million to modernize its site in Mississauga, Ontario, Canada into a consumer healthcare and prescription supply site. The investment enabled facility modifications, new equipment purchases, and enhanced manufacturing development capabilities. In addition, funds have supported the transfer to the site of Canadian consumer healthcare brand, Voltaren (diclofenac sodium), a topical pain reliever.

The site currently produces approximately 50 different products and exports 90% to more than 100 markets worldwide. With the investment, the facility, which now produces prescription drugs, will now produce an expanded portfolio of higher volume consumer healthcare products to increase the site’s production capacity from 30 million units a year to almost 50 million units by 2020.

Commercial production of Voltaren and the latest addition to the site’s production for Canada will begin by mid-2019.

Source: GlaxoSmithKline